Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs

Key Points

• Leerink Partners estimates Connect Biopharma's Q3 2025 earnings per share at ($0.25), compared to the consensus estimate of ($0.22) for the full year.
• Connect Biopharma recently reported ($0.19) EPS for a previous quarter, exceeding expectations by $0.07.
• Institutional investors own 58.72% of Connect Biopharma's stock, with new stakes added by firms such as XTX Topco Ltd and AlphaCore Capital LLC in Q2.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Connect Biopharma in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. Leerink Partnrs also issued estimates for Connect Biopharma's Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.37) EPS.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07.

CNTB has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Connect Biopharma in a research report on Wednesday, August 13th. Northland Capmk upgraded Connect Biopharma to a "strong-buy" rating in a research report on Tuesday, July 22nd.

Connect Biopharma Stock Performance

NASDAQ:CNTB opened at $2.05 on Monday. Connect Biopharma has a 12-month low of $0.51 and a 12-month high of $2.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.24 and a current ratio of 7.24. The business has a 50 day simple moving average of $1.52 and a 200 day simple moving average of $1.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Connect Biopharma during the 2nd quarter valued at $29,000. Koa Wealth Management LLC bought a new stake in Connect Biopharma during the 2nd quarter valued at $49,000. Finally, AlphaCore Capital LLC bought a new stake in Connect Biopharma during the 2nd quarter valued at $78,000. Institutional investors and hedge funds own 58.72% of the company's stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.